Lysine (lys) (methylated) Antikörper (Atto 390)

Produktnummer ABIN5650778

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch in ICC, IF, IP, ELISA und WB. Er zeigt eine Reaktivität gegenüber .

Kurzübersicht für Lysine (lys) (methylated) Antikörper (Atto 390) (ABIN5650778)

Target: Lysine (lys)

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Atto 390

Applikation: Immunocytochemistry (ICC), Immunofluorescence (IF), Immunoprecipitation (IP), ELISA, Western Blotting (WB)

Produktdetails

Bindungsspezifität: methylated

Spezifität: Detects proteins containing methylated lysine residues.

Aufreinigung: Protein A Purified

Immunogen: Methylated KLH Conjugated

Anwendungsinformationen

Applikationshinweise:

• WB (1:20000)
• ICC/IF (1:200)
• optimal dilutions for assays should be determined by the user.

Kommentare:

0.2-0.5 μg/ml of SPC-158 was sufficient for detection of the methylated histone by western blot analysis using melanoma cells in TBSt.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, 50 % glycerol, Storage buffer may change when conjugated

Lagerung: 4 °C

Informationen zur Lagerung: Conjugated antibodies should be stored at 4°C

Antigendetails

Target: Lysine (lys)

Andere Bezeichnung: Lysine

Substanzklasse: Amino Acid

Hintergrund: Post-translational modifications of proteins play critical roles in the regulation and function of many known biological processes. Proteins can be post-translationally modified in many different ways, and a common post-transcriptional modification of Lysine involves acetylation (1). The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (2). Protein posttranslational reversible lysine Nε-acetylation and deacetylation have been recognized as an emerging intracellular signaling mechanism that plays critical roles in regulating gene transcription, cell-cycle progression, apoptosis, DNA repair, and cytoskeletal organization (3). The regulation of protein acetylation status is impaired in the pathologies of cancer and polyglutamine diseases (4), and HDACs have become promising targets for anti-cancer drugs currently in development (5).